세계의 신장암 진단 및 치료 시장 보고서(2025년)

Kidney cancer diagnostics and therapeutics encompass methods and treatments utilized for diagnosing and managing kidney cancer, specifically renal cell carcinoma. The primary objectives of these approaches are to detect the presence of kidney cancer, assess its stage and extent, and offer appropriate treatment options to effectively manage the disease.

The main types of kidney cancer include clear cell RCC, papillary RCC, chromophobe RCC, urothelial carcinoma, transitional cell carcinoma, and others. Clear-cell renal cell carcinoma (RCC) is the predominant type, accounting for the majority of kidney cancer cases. RCC is further categorized into various subtypes based on the microscopic appearance of cancer cells. Kidney cancer diagnostics and therapeutics play a crucial role in managing clear cell renal cell carcinoma (RCC), the most prevalent subtype of kidney cancer. Treatment involves the use of components such as drugs and diagnostics, with diagnostics including biopsy, CT scan, nephro-ureteroscopy, intravenous pyelogram, and ultrasound. Therapies for kidney cancer include targeted therapy, immunotherapy, and chemotherapy. The main end-users of these diagnostics and therapeutics are hospitals, pharmaceutical labs, and genomic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The kidney cancer diagnostics and therapeutics market research report is one of a series of new reports from The Business Research Company that provides kidney cancer diagnostics and therapeutics market statistics, including kidney cancer diagnostics and therapeutics industry global market size, regional shares, competitors with a kidney cancer diagnostics and therapeutics market share, detailed kidney cancer diagnostics and therapeutics market segments, kidney cancer diagnostics and therapeutics market trends and opportunities, and any further data you may need to thrive in the kidney cancer diagnostics and therapeutics industry. This kidney cancer diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kidney cancer diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $4.1 billion in 2024 to $4.31 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to research on molecular biology, clinical trials and drug development, surgical innovations, genetic discoveries, healthcare access improvements.

The kidney cancer diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.65 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to biomarker research, genomic sequencing advances, telemedicine and remote consultations, precision medicine advancements, rapid diagnostic technologies. Major trends in the forecast period include palliative care integration, long-term survivorship care, nutrition and lifestyle intervention, expanded role of radiomics, liquid biopsies adoption.

The forecast of 7.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. providers by restricting access to next-generation sequencing panels and targeted kinase inhibitors imported from Switzerland and Japan, potentially compromising precision oncology approaches and increasing renal carcinoma treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in kidney cancer prevalence is poised to be a driving force behind the expansion of the kidney cancer diagnostics and therapeutics market. Kidney cancer, characterized by abnormal changes in normal kidney cells leading to uncontrolled growth and the formation of renal cortical tumors, necessitates effective diagnostics and therapeutics for optimal disease management. These components offer several advantages, including early detection, precise diagnosis, personalized medicine, and treatment monitoring. As per the American Society of Clinical Oncology (ASCO) in March 2023, it is estimated that 81,800 individuals in the United States will be diagnosed with kidney cancer in 2023, with a global impact of 431,288 cases in 2020. Consequently, the increasing prevalence of kidney cancer is expected to foster the growth of the kidney cancer diagnostics and therapeutics market.

The anticipated increase in healthcare spending is expected to drive the growth of the kidney cancer diagnostics and therapeutics market in the future. Healthcare spending encompasses the total financial resources allocated to the healthcare sector within a specific region, country, or organization. Investing in kidney cancer diagnostics and therapeutics is crucial for early detection, effective treatment, and improved patient outcomes. This investment addresses the diagnostic needs for timely intervention and the therapeutic requirements for optimal care, ultimately contributing to better overall health and reducing long-term healthcare costs. For instance, in March 2022, the Centers for Medicare & Medicaid Services, a US-based Department of Health and Human Services department, published the 2021-2030 National Health Expenditure (NHE) report, predicting an average annual increase in national health spending of 5.1% from 2021 to 2030, with total spending expected to reach approximately $6.8 trillion by 2030. Thus, the rise in healthcare spending is driving the growth of the kidney cancer diagnostics and therapeutics market.

Major companies in the kidney cancer diagnostics and therapeutics market are concentrating on the development of advanced treatments for renal cell carcinoma (RCC) to enhance patient outcomes and offer innovative treatment options tailored to the unique needs of individuals diagnosed with this complex disease. Research focused on renal cell carcinoma (RCC) is vital for the advancement of kidney cancer diagnostics and therapeutics, as it fosters the creation of new diagnostic techniques and targeted therapies that facilitate early diagnosis and personalized treatment plans for patients. For example, in December 2023, Merck, a US-based pharmaceutical company, introduced welireg (belzutifan), the first hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor approved for adult patients with advanced renal cell carcinoma (RCC) following previous treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This groundbreaking therapeutic class offers notable advantages, including enhanced progression-free survival and higher response rates compared to everolimus. The approval of WELIREG signifies a significant advancement in the kidney cancer diagnostics and therapeutics market, providing renewed hope for patients facing disease progression.

Major companies in the kidney cancer diagnostics and therapeutics market are focusing on adapting clinical trial collaborations to enhance research capabilities, speed up the development of innovative treatments, and improve patient access to cutting-edge therapies through shared expertise and resources. These collaborations are crucial for advancing kidney cancer diagnostics and therapeutics, as they combine expertise, resources, and data, thereby accelerating the creation of novel treatments and diagnostic tools, and enhancing patient outcomes through more effective therapies. For instance, in December 2023, Exelixis, Inc., a US-based company, announced a clinical trial collaboration with Arcus Biosciences Inc., also based in the US, to evaluate Zanzalintinib in combination with AB521 for patients with advanced renal cell carcinoma (RCC). This clinical trial, designated as STELLAR-009, is a Phase 1b/2 study aimed at assessing the safety, tolerability, and preliminary efficacy of Zanzalintinib when used alongside AB521. The trial will also evaluate the pharmacokinetics (PK) of these drugs in patients with advanced clear cell renal cell carcinoma (ccRCC) and other solid tumors.

In May 2023, Telix Pharmaceuticals Limited, an Australia-based biotechnology research firm, acquired QSAM Biosciences, Inc. for an undisclosed amount. This acquisition is intended to strengthen Telix's portfolio in the development of targeted radiopharmaceuticals, especially for cancer treatment. By incorporating QSAM's expertise and technologies, Telix aims to accelerate the advancement of its innovative therapies and expand its market presence in the precision medicine sector. QSAM Biosciences Inc. is a biotechnology research company based in the US.

Major companies operating in the kidney cancer diagnostics and therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited

North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the kidney cancer diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kidney cancer diagnostics and therapeutics market consists of revenues earned by entities by providing kidney cancer diagnostics and therapeutics services such as screening and diagnosis, treatment and therapeutics, radiation therapy, chemotherapy, and surgical interventions services. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney cancer diagnostics and therapeutics market also includes sales of imaging equipment, biopsy tools, surgical instruments, and supportive care products which are used in providing kidney cancer diagnostics and therapeutics services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kidney Cancer Diagnostics And Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kidney cancer diagnostics and therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kidney cancer diagnostics and therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The kidney cancer diagnostics and therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Clear Cell RCC; Papillary RCC; Chromophobe RCC; Urothelial Carcinoma And Transitional Cell Carcinoma; Other Cancer Types
• 2) By Component: Drugs; Diagnostics
• 3) By Diagnostics: Biopsy; CT Scan; Nephro-Ureteroscopy; Intravenous Pyelogram; Ultrasound
• 4) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy
• 5) By End-Users: Hospitals; Pharmaceutical Labs; Genomics Laboratories
• Subsegments:
• 1) By Clear Cell RCC: Stage I; Stage II; Stage III; Stage IV
• 2) By Papillary RCC: Type 1; Type 2
• 3) By Chromophobe RCC: Localized; Advanced
• 4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-muscle invasive; Muscle invasive; Metastatic
• 5) By Other Cancer Types: Collecting Duct Carcinoma; Renal Medullary Carcinoma; Other rare types
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Novartis AG; Sanofi S.A; Bristol-Myers Squibb Pharmaceuticals Limited; Thermo Fisher Scientific Inc.; AstraZeneca PLC; Abbott Laboratories; Takeda Pharmaceutical Company Limited; Eli Lilly and Co Ltd.; Amgen Inc.; Siemens Healthcare GmbH; Laboratory Corporation of America Holdings; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc.; Eisai Co. Ltd.; Illumina Inc.; PerkinElmer Inc.; Ipsen S.A; Bio-Rad Laboratories Inc.; QIAGEN NV; Exelixis Inc.; Myriad Genetics Inc.; Invitae Corporation; Guardant Health Inc.; GeneDx LLC; CD Genomics; Genpath Life Sciences Private Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Kidney Cancer Diagnostics And Therapeutics Market Characteristics

3. Kidney Cancer Diagnostics And Therapeutics Market Trends And Strategies

4. Kidney Cancer Diagnostics And Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Kidney Cancer Diagnostics And Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Kidney Cancer Diagnostics And Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Kidney Cancer Diagnostics And Therapeutics Market Growth Rate Analysis
• 5.4. Global Kidney Cancer Diagnostics And Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Kidney Cancer Diagnostics And Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Kidney Cancer Diagnostics And Therapeutics Total Addressable Market (TAM)

6. Kidney Cancer Diagnostics And Therapeutics Market Segmentation

• 6.1. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clear Cell RCC
• Papillary RCC
• Chromophobe RCC
• Urothelial Carcinoma And Transitional Cell Carcinoma
• Other Cancer Types
• 6.2. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs
• Diagnostics
• 6.3. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy
• CT Scan
• Nephro-Ureteroscopy
• Intravenous Pyelogram
• Ultrasound
• 6.4. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Immunotherapy
• Chemotherapy
• 6.5. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Pharmaceutical Labs
• Genomics Laboratories
• 6.6. Global Kidney Cancer Diagnostics And Therapeutics Market, Sub-Segmentation Of Clear Cell RCC, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stage I
• Stage II
• Stage III
• Stage IV
• 6.7. Global Kidney Cancer Diagnostics And Therapeutics Market, Sub-Segmentation Of Papillary RCC, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1
• Type 2
• 6.8. Global Kidney Cancer Diagnostics And Therapeutics Market, Sub-Segmentation Of Chromophobe RCC, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Localized
• Advanced
• 6.9. Global Kidney Cancer Diagnostics And Therapeutics Market, Sub-Segmentation Of Urothelial Carcinoma And Transitional Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-muscle invasive
• Muscle invasive
• Metastatic
• 6.10. Global Kidney Cancer Diagnostics And Therapeutics Market, Sub-Segmentation Of Other Cancer Types, BY Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Collecting Duct Carcinoma
• Renal Medullary Carcinoma
• Other rare types

7. Kidney Cancer Diagnostics And Therapeutics Market Regional And Country Analysis

• 7.1. Global Kidney Cancer Diagnostics And Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Kidney Cancer Diagnostics And Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market

• 8.1. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Kidney Cancer Diagnostics And Therapeutics Market

• 9.1. China Kidney Cancer Diagnostics And Therapeutics Market Overview
• 9.2. China Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Kidney Cancer Diagnostics And Therapeutics Market

• 10.1. India Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Kidney Cancer Diagnostics And Therapeutics Market

• 11.1. Japan Kidney Cancer Diagnostics And Therapeutics Market Overview
• 11.2. Japan Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Kidney Cancer Diagnostics And Therapeutics Market

• 12.1. Australia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Kidney Cancer Diagnostics And Therapeutics Market

• 13.1. Indonesia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Kidney Cancer Diagnostics And Therapeutics Market

• 14.1. South Korea Kidney Cancer Diagnostics And Therapeutics Market Overview
• 14.2. South Korea Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Kidney Cancer Diagnostics And Therapeutics Market

• 15.1. Western Europe Kidney Cancer Diagnostics And Therapeutics Market Overview
• 15.2. Western Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Kidney Cancer Diagnostics And Therapeutics Market

• 16.1. UK Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Kidney Cancer Diagnostics And Therapeutics Market

• 17.1. Germany Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Kidney Cancer Diagnostics And Therapeutics Market

• 18.1. France Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Kidney Cancer Diagnostics And Therapeutics Market

• 19.1. Italy Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Kidney Cancer Diagnostics And Therapeutics Market

• 20.1. Spain Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market

• 21.1. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market Overview
• 21.2. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Kidney Cancer Diagnostics And Therapeutics Market

• 22.1. Russia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Kidney Cancer Diagnostics And Therapeutics Market

• 23.1. North America Kidney Cancer Diagnostics And Therapeutics Market Overview
• 23.2. North America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Kidney Cancer Diagnostics And Therapeutics Market

• 24.1. USA Kidney Cancer Diagnostics And Therapeutics Market Overview
• 24.2. USA Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Kidney Cancer Diagnostics And Therapeutics Market

• 25.1. Canada Kidney Cancer Diagnostics And Therapeutics Market Overview
• 25.2. Canada Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Kidney Cancer Diagnostics And Therapeutics Market

• 26.1. South America Kidney Cancer Diagnostics And Therapeutics Market Overview
• 26.2. South America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Kidney Cancer Diagnostics And Therapeutics Market

• 27.1. Brazil Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Kidney Cancer Diagnostics And Therapeutics Market

• 28.1. Middle East Kidney Cancer Diagnostics And Therapeutics Market Overview
• 28.2. Middle East Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Kidney Cancer Diagnostics And Therapeutics Market

• 29.1. Africa Kidney Cancer Diagnostics And Therapeutics Market Overview
• 29.2. Africa Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Kidney Cancer Diagnostics And Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Kidney Cancer Diagnostics And Therapeutics Market Competitive Landscape
• 30.2. Kidney Cancer Diagnostics And Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Kidney Cancer Diagnostics And Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A
• 31.2. Bristol-Myers Squibb Pharmaceuticals Limited
• 31.3. Thermo Fisher Scientific Inc.
• 31.4. AstraZeneca PLC
• 31.5. Abbott Laboratories
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Co Ltd.
• 31.8. Amgen Inc.
• 31.9. Siemens Healthcare GmbH
• 31.10. Laboratory Corporation of America Holdings
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Astellas Pharma Inc.
• 31.13. Eisai Co. Ltd.
• 31.14. Illumina Inc.
• 31.15. PerkinElmer Inc.

32. Global Kidney Cancer Diagnostics And Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Kidney Cancer Diagnostics And Therapeutics Market

34. Recent Developments In The Kidney Cancer Diagnostics And Therapeutics Market

35. Kidney Cancer Diagnostics And Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Kidney Cancer Diagnostics And Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Kidney Cancer Diagnostics And Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Kidney Cancer Diagnostics And Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer